This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/mesh/concept/
n9http://linked.opendata.cz/resource/drugbank/company/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01134/identifier/chemspider/
n17http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01134/identifier/pharmgkb/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01134/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01134/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB01134/identifier/drugbank/

Statements

Subject Item
n2:DB01134
rdf:type
n3:Drug
n3:description
Desoxycorticosterone Pivalate is a mineralocorticoid hormone and an analog of desoxycorticosterone. It is white, odorless, and stable in air. It is practically insoluble in water, sparingly soluble in acetone, slightly soluble in methanol, ether and vegetable oils. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
n3:group
experimental
n3:indication
Examined for treatment of adrenocortical insufficiency especially in multiple sclerosis, congenital cerebral palsy, polyarteritis nodosa, and rheumatoid arthritis. Currently only approved in treating cats and dogs for the treatment of Addison's disease.
owl:sameAs
n16:DB01134 n17:DB01134
dcterms:title
Desoxycorticosterone Pivalate
adms:identifier
n6:DB01134 n7:12574 n8:46506381 n12:PA449245 n13:13126
n3:mechanismOfAction
Desoxycorticosterone Pivalate binds to the mineralocorticoid receptor. Mineralocorticoids are a family of steroids, secreted by the adrenal cortex, necessary for the regulation of a number of metabolic processes including electrolyte regulation. Desoxycorticosterone pivalate exerts its effect through its interaction with the mineralocorticoid receptor (MR), whereby it reacts with the receptor proteins to form a steroid-receptor complex. This complex moves into the nucleus, where it binds to chromatin which results in genetic transcription of cellular DNA to messenger RNA. The steroid hormones appear to induce transcription and synthesis of specific proteins, which produce the physiological effects seen after administration.
n3:packager
n9:271B4650-363D-11E5-9242-09173F13E4C5
n3:synonym
Desoxycorticosterone Trimethylacetate Deoxycortone Trimethylacetate Deoxycortolone Pivalate Deoxycortone Pivalate DTMA Deoxycorticosterone Pivalate Deoxycorticosterone Trimethylacetate DOCP Desoxycortone Pivalate
n3:toxicity
Symptoms of overdose include polyuria, polydipsia, increased blood volume, edema, and cardiac enlargement.
n3:proteinBinding
90%
n10:hasConcept
n11:M0071704
n3:IUPAC-Name
n4:271B4655-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B465B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B465A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4657-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4658-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4659-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4653-363D-11E5-9242-09173F13E4C5 n4:271B466B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4651-363D-11E5-9242-09173F13E4C5 n4:271B4654-363D-11E5-9242-09173F13E4C5 n4:271B466C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4652-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4661-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4662-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B465C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B465D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B465F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B465E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4660-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
808-48-0
n3:Bioavailability
n4:271B4667-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4669-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B466A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4666-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4665-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4668-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4656-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4663-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4664-363D-11E5-9242-09173F13E4C5